Histrelin
Top View
- CP.PHAR.172 Histrelin Acetate (Vantas, Supprelin
- Gonadotropin Releasing Hormone Analogs (Gnrh)
- Partial Androgen Suppression Consequent to Increased Secretion of Adrenal Androgens in a Patient with Prostate Cancer Treated with Long-Acting Gnrh Agonists
- Gnrh Gender Dysphoria Page: 1 of 5
- Therapeutic Class Overview Gonadotropin-Releasing Hormone (Gnrh) Agonists/ Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
- The Histrelin Implant: a Novel Treatment for Central Precocious Puberty
- Vantas®) 50Mg Subdermal Implant ♦ Histrelin Is Indicated for the Prostate Cancer Is the Uncontrolled
- Comparison of Efficacy of Two Dose Rates of Histrelin to Human
- Appendix a - Product Name Index
- Histrelin Acetate (Vantas, Supprelin LA) Reference Number: ERX.SPA.146 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log
- Download Full Instructions for Implanting And
- Clinical Criteria
- 020263Orig1s042
- Short-Term Buserelin Administration Induces Apoptosis and Morphological Changes in Adult Rat Testes1
- Sections Or Subsections Omitted from the Full
- Download Product Insert (PDF)
- The Legally Binding Text Is the Original French Version TRANSPARENCY
- Xtandi (Enzalutamide)